Prime Medicine, Inc.
PRME
$3.27
-$0.03-0.91%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.89% | 55.28% | 647.13% | 739.42% | 550.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.89% | 55.28% | 647.13% | 739.42% | 550.76% |
| Cost of Revenue | -2.69% | 5.19% | -1.55% | -4.98% | -22.98% |
| Gross Profit | 2.94% | -3.87% | 5.77% | 8.53% | 25.18% |
| SG&A Expenses | 7.99% | 4.36% | -2.03% | 11.55% | 15.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.13% | 3.67% | -1.71% | -0.68% | 5.08% |
| Operating Income | -0.05% | -2.91% | 4.15% | 2.76% | -3.47% |
| Income Before Tax | 1.87% | -2.69% | 9.99% | 8.40% | 1.12% |
| Income Tax Expenses | -- | -- | -- | -- | -335.09% |
| Earnings from Continuing Operations | 1.80% | -2.69% | 9.99% | 8.35% | 1.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.80% | -2.69% | 9.99% | 8.35% | 1.22% |
| EBIT | -0.05% | -2.91% | 4.15% | 2.76% | -3.47% |
| EBITDA | 0.43% | -2.39% | 4.99% | 3.56% | -2.73% |
| EPS Basic | 22.35% | 17.13% | 29.70% | 27.69% | 25.20% |
| Normalized Basic EPS | 21.03% | 17.49% | 25.40% | 23.54% | 22.08% |
| EPS Diluted | 22.35% | 17.13% | 29.70% | 27.69% | 25.20% |
| Normalized Diluted EPS | 21.03% | 17.49% | 25.40% | 23.54% | 22.08% |
| Average Basic Shares Outstanding | 28.62% | 26.04% | 26.52% | 25.20% | 32.04% |
| Average Diluted Shares Outstanding | 28.62% | 26.04% | 26.52% | 25.20% | 32.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |